8-K: Vivani Medical Delays Cortigent Spin-Off Record Date

Vivani Medical, Inc. announced the temporary withdrawal of the record date for its Cortigent neuromodulation subsidiary spin-off due to U.S. federal government shutdown delays.

Summary

• Vivani Medical, Inc. (VANI) has temporarily withdrawn the previously announced record date for the planned spin-off of its wholly-owned subsidiary, Cortigent, Inc.
• The record date of October 8, 2025, for the proposed spin-off has been withdrawn.
• The delay is attributed to the current shutdown of the U.S. federal government.
• Vivani expects to reestablish and announce a new record date as soon as possible.
• Cortigent is focused on developing brain implant devices utilizing cutting-edge neuromodulation technology.
• ThinkEquity is serving as the exclusive financial advisor to Cortigent for the spin-off transaction.

Sentiment

Score: 4

Explanation: The delay of a significant corporate action like a spin-off is a negative event, introducing uncertainty. However, the underlying businesses (Vivani's NanoPortal and Cortigent's neuromodulation technology with FDA Breakthrough Device designation and promising study results) still hold long-term potential. The delay is due to an external, non-company-specific factor (government shutdown).

Positives

• Cortigent's Orion Visual Cortical Prosthesis System has received an FDA Breakthrough Device designation.
• The Orion system successfully completed a 6-year Early Feasibility Study in 2025, demonstrating promising safety and efficacy results.
• Cortigent's predecessor, Second Sight Medical Products, previously marketed Argus II, which was the first and only medical device to obtain FDA approval to treat a rare form of blindness, helping hundreds of patients.
• Vivani's proprietary NanoPortal platform is developing miniature, ultra long-acting drug implants for metabolic diseases, including obesity and type 2 diabetes, aiming to improve patient adherence and tolerability.

Negatives

• The temporary withdrawal of the record date for the Cortigent spin-off introduces uncertainty and delays a significant corporate action.
• The spin-off process is delayed due to an external factor, the U.S. federal government shutdown.

Risks

• Risks that the spin-off will not be completed in a timely manner or at all.
• Risks of failure to satisfy any conditions to the spin-off.
• Risks of failure of the spin-off to qualify for non-recognition of gain or loss for U.S. federal income tax purposes.
• Uncertainty regarding whether the anticipated benefits of the spin-off can be achieved.
• Risks of unexpected costs or delays associated with the spin-off.
• Risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies, and objectives.
• Risks related to market conditions and Cortigent's ability to complete its spin-off.
• Cortigent's history of losses and its ability to access additional capital or otherwise fund its business and advance its product candidates and pre-clinical programs.

Future Outlook

Vivani expects to reestablish and announce a new record date for the Cortigent spin-off as soon as possible. The company continues to develop its NanoPortal platform for GLP-1 based implants for metabolic diseases. Cortigent continues to develop its neurostimulation brain-computer interfaces, including the Orion system and technology for stroke recovery.

Management Comments

• Vivani expects to reestablish and announce a new record date as soon as possible.

Industry Context

The filing highlights developments in two high-growth sectors: neuromodulation and brain-computer interfaces (BCIs) for conditions like blindness and paralysis, and long-acting drug implants for chronic metabolic diseases (e.g., GLP-1 for obesity/diabetes). Both fields are experiencing significant innovation and investment, driven by substantial unmet medical needs and rapid technological advancements. The delay of the spin-off due to a government shutdown is an external, non-industry-specific factor, but its impact on corporate actions can be significant across various sectors.

Comparison to Industry Standards

• Cortigent's predecessor, Second Sight Medical Products, successfully marketed Argus II, which was the first and only medical device to obtain FDA approval to treat a rare form of blindness, setting a high benchmark for regulatory success in the BCI space.
• The Orion Visual Cortical Prosthesis System's FDA Breakthrough Device designation indicates its potential to offer more effective treatment for life-threatening or irreversibly debilitating conditions compared to existing therapies, aligning with top-tier medical device innovation.
• The completion of a 6-year Early Feasibility Study for Orion with promising safety and efficacy results demonstrates a rigorous and extended development pathway, comparable to robust clinical trials in the advanced medical device industry.

Stakeholder Impact

• Shareholders: The delay in the spin-off could impact shareholder value and the timeline for receiving shares in Cortigent, introducing uncertainty regarding the separation of the two entities.
• Employees: The delay might create uncertainty for employees of Cortigent regarding the timing of their transition to a fully independent company.
• Investors: The delay could affect investor sentiment and potentially the stock price of Vivani Medical, Inc. due to increased uncertainty.

Next Steps

• Vivani expects to reestablish and announce a new record date for the Cortigent spin-off as soon as possible.
• Cortigent will continue to develop its neurostimulation brain-computer interfaces, including the Orion system.
• Vivani will continue to develop its GLP-1 based implants using the NanoPortal platform.

Key Dates

Recommendation

The temporary delay of the Cortigent spin-off is a negative development, introducing uncertainty and potentially impacting the timeline for unlocking value from the subsidiary. However, the delay is attributed to an external factor (government shutdown) rather than fundamental issues with either Vivani's or Cortigent's core businesses or technologies. Cortigent's FDA Breakthrough Device designation and promising study results, along with Vivani's NanoPortal platform, still represent significant long-term potential. Investors should hold to await the re-establishment of a new record date and further clarity on the spin-off, as the underlying assets remain valuable.

Keywords

Vivani Medical, VANI, Cortigent, spin-off, neuromodulation, brain implant, FDA Breakthrough Device, NanoPortal, GLP-1, biopharmaceutical, medical device, government shutdown, corporate action